Use

The JAK2 V617F mutation is present in approximately 90% of polycythemia vera (PV) cases and approximately half of primary myelofibrosis (PMF) or essential thrombocythemia (ET). Quantitation of V617F is useful for monitoring myeloproliferative neoplasm (MPN) patients’ response to clinical treatment because mutational load correlates with disease course, making it a useful predictive marker.